Protracted cognitive effects produced by clonidine in Macaca nemestrina performing a delayed matching task.
BACKGROUND
The alpha(2)-adrenergic receptor agonist clonidine was examined for its ability to improve working memory in monkeys.


METHODS
Clonidine (0.116-34.8 microg/kg) was administered to six pigtail macaques in their performance of a computer-assisted delayed matching-to-sample (DMTS) task.


CONCLUSIONS
During DMTS sessions initiated 1 hour after dosing, there was a slight improvement in mean task accuracy (long delay trials; 0.116-microg/kg). On the following day, there was continued and added improvement in accuracies associated with the long delay trials. On the day following 1.16-microg/kg, the entire memory retention curve was shifted to the right of vehicle. When the animals were again tested 48 hours after dosing (no pretreatment), these two patterns of task enhancement were continued and enhanced. Mean task accuracy associated with long delay trials was significantly increased by 14.2% trials correct when animals were originally treated with 0.116-microg/kg of clonidine. Mean task accuracy associated with medium delay trials was significantly increased by 11.8% trials correct when animals were treated with 1.16-microg/kg. On the sixth day after clonidine, task accuracies were still significantly improved during medium delay trials after 0.116-microg/kg. Median sample and choice latencies were not significantly influenced by clonidine treatment. These findings are consistent with the ability of clonidine to induce a protracted improvement in aspects of working memory.


CONCLUSIONS
Early (attentional) and late (retention) components of memory appeared to be differentially sensitive to the dose of clonidine. Central alpha(2)-adrenergic receptors should be considered legitimate drug targets for future compound development for cognition enhancement.
Buccafusco
Jerry J
JJ
Alzheimer's Research Center, Medical College of Georgia, Augusta, GA 30912-2300, USA. jbuccafu@mcg.edu
Webster
Scott J
SJ
Terry
Alvin V
AV
Kille
Nancy
N
Blessing
Donna
D
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000818:Animals; D003000:Clonidine / Q000494:pharmacology*; D003071:Cognition / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D008254:Macaca nemestrina; D008297:Male; D008568:Memory / Q000187:drug effects; D008570:Memory, Short-Term / Q000187:drug effects*; D011597:Psychomotor Performance / Q000187:drug effects*
D000316:Adrenergic alpha-Agonists; D003000:Clonidine
J Physiol. 1999 Sep 1;519 Pt 2:439-49
10457061
Behav Pharmacol. 2006 Nov;17(7):581-7
17021390
Cereb Cortex. 1993 Jul-Aug;3(4):304-12
8400808
J Psychopharmacol. 2007 Mar;21(2):171-8
17329297
J Clin Psychopharmacol. 1999 Oct;19(5):444-9
10505586
Psychoneuroendocrinology. 1993;18(1):45-55
8097332
Neuropsychopharmacology. 2000 Sep;23(3):240-9
10942848
J Neurosci. 1988 Nov;8(11):4287-98
2903226
Cogn Behav Neurol. 2006 Dec;19(4):204-7
17159617
Psychopharmacology (Berl). 2002 Jul;162(3):304-12
12122489
Trends Pharmacol Sci. 2005 Jul;26(7):352-60
15946748
J Pharmacol Exp Ther. 1999 Feb;288(2):798-804
9918591
Neurotoxicol Teratol. 1998 Sep-Oct;20(5):493-502
9761587
CNS Drug Rev. 2005 Autumn;11(3):229-52
16389292
Behav Neural Biol. 1992 Sep;58(2):152-8
1456935
Cell. 2007 Apr 20;129(2):397-410
17448997
Learn Mem. 2006 Nov-Dec;13(6):770-6
17101879
Psychopharmacology (Berl). 1986;88(3):374-80
3083458
Neuropsychopharmacology. 1999 Nov;21(5):611-21
10516957
J Child Adolesc Psychopharmacol. 2007 Aug;17(4):393-406
17822336
Pharmacol Biochem Behav. 1997 May-Jun;57(1-2):231-41
9164577
Neuroscience. 1999;92(3):975-82
10426537
Neuropsychopharmacology. 1999 May;20(5):460-70
10192826
J Paediatr Child Health. 2007 Jan-Feb;43(1-2):19-24
17207050
Pharmacol Biochem Behav. 1991 May;39(1):79-84
1924516